Results 131 to 140 of about 3,958 (169)

Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma [PDF]

open access: yesCancers, 2020
Mitotane is the main option of treatment for advanced adrenocortical carcinoma (ACC). However, limited evidence is available regarding the impact of plasma mitotane levels on patient outcome. To address this question, we retrospectively analyzed patients
Marco Russo   +2 more
exaly   +4 more sources

Metabolic and Endocrine Toxicities of Mitotane: A Systematic Review [PDF]

open access: yesCancers, 2021
BACKGROUND Mitotane is currently used for the treatment of unresectable adrenocortical cancer and as adjuvant therapy in patients with a high risk of recurrence.
Rosa Lauretta   +2 more
exaly   +4 more sources

Lipoprotein-Free Mitotane Exerts High Cytotoxic Activity in Adrenocortical Carcinoma

open access: yesJournal of Clinical Endocrinology and Metabolism, 2015
International audienceContext: Mitotane (o,p’-DDD), the only approved drug for advanced adrenocortical carcinoma (ACC), is a lipophilic agent that accumulates into circulating lipoprotein fractions and high lipid-containing tissues. Objective: The aim of
Sophie Broutin   +2 more
exaly   +2 more sources

Development of microemulsion of mitotane for improvement of oral bioavailability

open access: yesDrug Development and Industrial Pharmacy, 2010
International audienceBACKGROUND: Mitotane (o,p'-DDD) is considered to be the drug of choice in the treatment of nonresectable and metastasized adrenocortical carcinoma.
Stéphane Gibaud, Alain Astier
exaly   +2 more sources

Inhibitory effects of mitotane on viability and secretory activity in mouse gonadotroph cell lines

open access: yesReproductive Toxicology, 2014
Mitotane represents the mainstay medical treatment for metastatic, inoperable or recurrent adrenocortical carcinoma. Besides the well-known adverse events, mitotane therapy is associated also with endocrinological effects, including sexual and ...
Maria Chiara Zatelli   +2 more
exaly   +2 more sources

Home - About - Disclaimer - Privacy